The American Medical Association (AMA) Department of Drugs, the American Society for Clinical Pharmacology, and 512 consultants contributed comments for this edition. The preface states that the FDA-approved labeling is not necessarily a limitation of the use of the drug in individual patients, but the statement is not supported by quotations of court decisions (practitioner beware!). The preface contains also an index of “New Drugs” and of “Investigational Drugs” and their respective indications.
Chapters 1–3 give information on prescription practices, regulatory agencies, drug responses and dosing, and on drug interactions and adverse reactions. Table 2 is selective for adverse reactions during pregnancy. The subsequent chapters are arranged by disease categories covering the field of internal medicine. Each of the chapters has a clinical section, including therapy, and a section on drug evaluation. We reviewed Chapter 77, Antiprotozoal Agents, and Chapter 78, Anthelminthics.